ERAS 007
Alternative Names: ASN 007A; ASN-007; ERAS-007Latest Information Update: 13 Jul 2024
Price :
$50 *
At a glance
- Originator Asana BioSciences
- Developer Erasca
- Class Amines; Antineoplastics; Halogenated hydrocarbons; Imidazoles; Pyrimidines; Small molecules
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 31 May 2024 Updated efficacy and adverse events data from a phase I/II trial in Colorectal cancer and Pancreatic cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Jun 2023 Updated pharmacokinetics, safety and efficacy data from the phase Ib/II HERKULES-3 trial in Pancreatic cancer released by Erasca
- 02 Jun 2023 Pharmacokinetics and adverse events data from phase-Ib/II HERKULES-3 trial in Colorectal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)